Zilovertamab (cirmtuzumab, UC-961), an anti-ROR1 monoclonal antibody developed as a ROR1 antagonist, has shown encouraging therapeutic effects in patients with B-CLL and MCL with a good safety profile (14, 15). Here, ROR1 is linked to B-cell chronic lymphocytic leukemia.